Skip to content

Study · Animal study (in vivo) · rat · 1996

5 results

The growth hormone-releasing peptide KP-102 induces c-fos expression in the arcuate nucleus.

Kamegai J, Hasegawa O, Minami S, Sugihara H, Wakabayashi I

Brain research. Molecular brain research1 Jul 1996Cited by 16 (Europe PMC)

PMID8804723 (opens in a new tab)DOI10.1016/0169-328x(96)00020-4 (opens in a new tab)PepBankPUB-08804723
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In hypophysectomized rats, KP-102 treatment caused transient c-fos expression selectively in the ventromedial and ventrolateral regions of the arcuate nucleus.

    In plain wordsIn rats without a pituitary gland, KP-102 briefly switched on the c-fos gene in two parts of the arcuate nucleus in the brain.

    Peptide
    GHRP-2
    Outcome
    Increasec-fos expression in the arcuate nucleus
    Study

    ratn: not reported in source

    Hypophysectomized adult male Wistar rats
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · indwelling right atrial cannulaAs given in this study (rat).

    Source sentences

    Summary
    KP-102 treatment was accompanied by transient expression of the c-fos gene selectively in the ventromedial and ventrolateral regions of the arcuate nucleus (ARC).
    1 context sentence
    Summary · context
    Hypophysectomized adult male Wistar rats were administered KP-102 through an indwelling right atrial cannula.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In hypophysectomized rats given KP-102, the distribution of c-fos expressing cells overlapped that of GRF mRNA-containing neurons in the ventrolateral region.

    In plain wordsIn rats without a pituitary gland, cells activated by KP-102 overlapped with GRF-producing nerve cells in one part of the arcuate nucleus.

    Peptide
    GHRP-2
    Outcome
    Not applicableOverlap of c-fos cells with GRF neurons in the ventrolateral region
    Study

    ratn: not reported in source

    Hypophysectomized adult male Wistar rats
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · indwelling right atrial cannulaAs given in this study (rat).

    Source sentences

    Summary
    The distribution of c-fos gene-expressing cells overlapped that of GRF mRNA-containing neurons in the ventrolateral region on adjacent sections
    1 context sentence
    Summary · context
    Hypophysectomized adult male Wistar rats were administered KP-102 through an indwelling right atrial cannula.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In hypophysectomized rats given KP-102, few c-fos mRNA signals were detected in the dorsomedial region where somatostatin mRNA signals were localized.

    In plain wordsIn rats without a pituitary gland, KP-102 caused few c-fos signals in the arcuate region that holds somatostatin cells.

    Peptide
    GHRP-2
    Outcome
    No significant changec-fos signals in the dorsomedial region with somatostatin mRNA
    Study

    ratn: not reported in source

    Hypophysectomized adult male Wistar rats
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · indwelling right atrial cannulaAs given in this study (rat).

    Source sentences

    Summary
    few c-fos mRNA signals were detected in the dorsomedial region where somatostatin mRNA signals were localized.
    1 context sentence
    Summary · context
    Hypophysectomized adult male Wistar rats were administered KP-102 through an indwelling right atrial cannula.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In hypophysectomized rats given KP-102, twenty-three percent of c-fos mRNA-containing cells were GRF neurons.

    In plain wordsIn rats without a pituitary gland, about one in four cells activated by KP-102 were GRF nerve cells.

    Peptide
    GHRP-2
    Outcome
    Not applicableShare of c-fos cells that were GRF neurons
    Study

    ratn: not reported in source

    Hypophysectomized adult male Wistar rats
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · indwelling right atrial cannulaAs given in this study (rat).

    Source sentences

    Summary
    Twenty-three percent of c-fos mRNA-containing cells were GRF neurons, comprising 20% of the GRF neurons in the ARC.
    1 context sentence
    Summary · context
    Hypophysectomized adult male Wistar rats were administered KP-102 through an indwelling right atrial cannula.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In hypophysectomized rats given KP-102, the c-fos mRNA-containing GRF neurons made up 20% of the GRF neurons in the arcuate nucleus.

    In plain wordsIn rats without a pituitary gland, KP-102 activated about one in five of the GRF nerve cells in the arcuate nucleus.

    Peptide
    GHRP-2
    Outcome
    Not applicableShare of arcuate GRF neurons that expressed c-fos
    Study

    ratn: not reported in source

    Hypophysectomized adult male Wistar rats
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · indwelling right atrial cannulaAs given in this study (rat).

    Measurements

    GRF neurons in the ARC expressing c-fos
    20%
    arcuate nucleus

    Source sentences

    Summary
    Twenty-three percent of c-fos mRNA-containing cells were GRF neurons, comprising 20% of the GRF neurons in the ARC.
    1 context sentence
    Summary · context
    Hypophysectomized adult male Wistar rats were administered KP-102 through an indwelling right atrial cannula.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 2

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.